Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea |
Baek, Seon Ha
(Department of Internal Medicine, Seoul National University Hospital)
Kim, Hyunsuk (Department of Internal Medicine, Seoul National University Hospital) Lee, Jeonghwan (Department of Internal Medicine, Seoul National University Hospital) Kim, Dong Ki (Department of Internal Medicine, Seoul National University Hospital) Oh, Kook-Hwan (Department of Internal Medicine, Seoul National University Hospital) Kim, Yon Su (Department of Internal Medicine, Seoul National University Hospital) Han, Jin Suk (Department of Internal Medicine, Seoul National University Hospital) Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital) Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital) Joo, Kwon-Wook (Department of Internal Medicine, Seoul National University Hospital) |
1 | Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly: a mini-review. Gerontology 2010;56:303-309. DOI |
2 | Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322-328. DOI ScienceOn |
3 | Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-113. DOI |
4 | Rini BI, Garcia JA, Cooney MM, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010;28:e284-e285. DOI |
5 | Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9-17. DOI |
6 | Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338. DOI ScienceOn |
7 | Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930. DOI ScienceOn |
8 | Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol 2010;21:1618-1622. DOI |
9 | van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-2995. DOI |
10 | Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-82. DOI |
11 | Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011;117:c312-c319. DOI |
12 | Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. DOI ScienceOn |
13 | Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230. |
14 | Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. DOI ScienceOn |
15 | National Cancer Institute. NCI Term Browser: common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]. Rockville (MD): National Cancer Institute, c2010 [cited 2010 Jun 14]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. |
16 | Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. DOI ScienceOn |
17 | Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100:282-284. DOI |
18 | Obhrai JS, Patel TV, Humphreys BD. The case/progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008;74:685-686. DOI ScienceOn |
19 | Kim HS, Hong MH, Kim K, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 2011;80:395-405. DOI |
20 | Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009;4:121-133. DOI |
21 | Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24:673-675. |
22 | Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007;5:341-344. DOI |
23 | Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682-685. |
24 | Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010;46:439-448. DOI ScienceOn |
25 | Szmit S, Langiewicz P, Zlnierek J, et al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2012;35:18-25. DOI |
26 | Rini BI. Biomarkers: hypertension following anti-angiogenesis therapy. Clin Adv Hematol Oncol 2010;8:415-416. |
27 | Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-394. |
28 | Oudard S, Beuselinck B, Decoene J, Albers P. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011;37:178-184. DOI |
29 | Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18:1117. DOI |
30 | Machado FG, Kuriki PS, Fujihara CK, et al. Chronic VEGF blockade worsens glomerular injury in the remnant kidney model. PLoS One 2012;7:e39580. DOI |
31 | Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol 2009;2:172-176. DOI |
32 | Kim HW, Lim JH, Kim MY, et al. Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis. Nephrol Dial Transplant 2011;26:1173-1188. DOI ScienceOn |
![]() |